Ventricular arrhythmias (VAs) have touched many lives, too often in tragic circumstances
in the form of the sudden death of a family member or friend. Our understanding of
sudden death has evolved as we journeyed from understanding VAs, to understanding
the factors leading to their onset, and finally the interventions that can change
the course of the natural history. In the early phase of recognition, the scope of
the problem was compelling, with 1 in 1000 individuals suffering sudden death annually
and being only rarely successfully resuscitated. Improvements in the treatment of
atherosclerotic heart disease, ventricular dysfunction, heart failure, and VAs have,
however, increased survival rate, reduced sudden death incidence, and improved quality
of life in affected patients.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Paroxysmal ventricular tachycardia.Br Heart J. 1943; 5: 33-54
- Paroxysmal ventricular tachycardia.Br Heart J. 1964; 26: 441-451
- Survivors of prehospital cardiac arrest.JAMA. 1982; 247: 1485-1490
- Frequency of sudden cardiac death and profiles of risk.Am J Cardiol. 1997; 80 (:10F-9F)
- Prediction of sudden cardiac arrest in the general population: review of traditional and emerging risk factors.Can J Cardiol. 2022; 38: 465-478
- Predicting sudden cardiac death in genetic heart disease.Can J Cardiol. 2022; 38: 479-490
- Lifestyle considerations in genetic cardiac conditions associated with sudden cardiac death.Can J Cardiol. 2022; 38: 544-548
- Evolution of devices to prevent sudden cardiac death: contemporary clinical impacts.Can J Cardiol. 2022; 38: 515-525
- Primary prevention implantable cardioverter-defibrillators in adults with congenital heart disease: recommendations from professional societies.Can J Cardiol. 2022; 38: 536-539
- Responding to cardiac arrest in the community in the digital age.Can J Cardiol. 2022; 38: 491-501
- When to suspect and investigate cardiac sarcoidosis.Can J Cardiol. 2022; 38: 549-551
- Myocardial inflammation and sudden death in the inherited cardiomyopathies.Can J Cardiol. 2022; 38: 427-438
- Sudden cardiac death in diabetes and obesity: mechanisms and therapeutic strategies.Can J Cardiol. 2022; 38: 418-426
- Ventricular tachycardia burden and mortality: association or causality?.Can J Cardiol. 2022; 38: 454-464
- Recent insights into mechanisms and clinical approaches to electrical storm.Can J Cardiol. 2022; 38: 439-453
- When to consider ablation for premature ventricular complexes?.Can J Cardiol. 2022; 38: 540-543
- Newer methods for ventricular tachycardia ablation and when to use them.Can J Cardiol. 2022; 38: 502-514
Article info
Publication history
Published online: February 17, 2022
Accepted:
February 8,
2022
Received:
February 8,
2022
Footnotes
See page 416 for disclosure information.
Identification
Copyright
© 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
